vs
Amarin Corp plc（AMRN）与Ouster, Inc.（OUST）财务数据对比。点击上方公司名可切换其他公司
Ouster, Inc.的季度营收约是Amarin Corp plc的1.4倍（$62.2M vs $45.1M），Ouster, Inc.净利率更高（6.4% vs -23.3%，领先29.7%），Ouster, Inc.同比增速更快（106.6% vs 7.0%），过去两年Ouster, Inc.的营收复合增速更高（51.8% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
Ouster, Inc.是总部位于美国加利福尼亚州旧金山的激光雷达技术企业，主打高分辨率数字化3D激光雷达传感器，产品广泛应用于自动驾驶车辆、工业自动化、机器人、无人机、地图测绘、国防及安防等领域。
AMRN vs OUST — 直观对比
营收规模更大
OUST
是对方的1.4倍
$45.1M
营收增速更快
OUST
高出99.6%
7.0%
净利率更高
OUST
高出29.7%
-23.3%
两年增速更快
OUST
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $62.2M |
| 净利润 | $-10.5M | $4.0M |
| 毛利率 | — | 60.2% |
| 营业利润率 | 35.5% | 41.2% |
| 净利率 | -23.3% | 6.4% |
| 营收同比 | 7.0% | 106.6% |
| 净利润同比 | 33.0% | — |
| 每股收益（稀释后） | — | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNOUST
| Q1 26 | $45.1M | $62.2M | ||
| Q4 25 | $49.2M | $62.2M | ||
| Q3 25 | $49.7M | $39.5M | ||
| Q2 25 | $72.7M | $35.0M | ||
| Q1 25 | $42.0M | $32.6M | ||
| Q4 24 | $62.3M | $30.1M | ||
| Q3 24 | $42.3M | $28.1M | ||
| Q2 24 | $67.5M | $27.0M |
净利润AMRNOUST
| Q1 26 | $-10.5M | $4.0M | ||
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-7.7M | $-21.7M | ||
| Q2 25 | $-14.1M | $-20.6M | ||
| Q1 25 | $-15.7M | $-22.0M | ||
| Q4 24 | $-48.6M | — | ||
| Q3 24 | $-25.1M | $-25.6M | ||
| Q2 24 | $1.5M | $-23.9M |
毛利率AMRNOUST
| Q1 26 | — | 60.2% | ||
| Q4 25 | 47.1% | 60.2% | ||
| Q3 25 | 44.7% | 42.1% | ||
| Q2 25 | 69.2% | 45.2% | ||
| Q1 25 | 59.8% | 41.3% | ||
| Q4 24 | -15.4% | 43.8% | ||
| Q3 24 | 38.5% | 38.3% | ||
| Q2 24 | 63.4% | 33.7% |
营业利润率AMRNOUST
| Q1 26 | 35.5% | 41.2% | ||
| Q4 25 | -12.9% | 1.5% | ||
| Q3 25 | -22.4% | -61.4% | ||
| Q2 25 | -22.0% | -76.5% | ||
| Q1 25 | -39.9% | -73.0% | ||
| Q4 24 | -84.3% | -85.1% | ||
| Q3 24 | -59.5% | -98.0% | ||
| Q2 24 | -0.8% | -93.6% |
净利率AMRNOUST
| Q1 26 | -23.3% | 6.4% | ||
| Q4 25 | -2.5% | — | ||
| Q3 25 | -15.6% | -55.0% | ||
| Q2 25 | -19.4% | -58.8% | ||
| Q1 25 | -37.4% | -67.5% | ||
| Q4 24 | -78.0% | — | ||
| Q3 24 | -59.4% | -91.1% | ||
| Q2 24 | 2.3% | -88.4% |
每股收益（稀释后）AMRNOUST
| Q1 26 | — | $0.06 | ||
| Q4 25 | $0.00 | $0.10 | ||
| Q3 25 | $-0.02 | $-0.37 | ||
| Q2 25 | $-0.03 | $-0.38 | ||
| Q1 25 | $-0.04 | $-0.42 | ||
| Q4 24 | $-0.12 | $-0.46 | ||
| Q3 24 | $-0.06 | $-0.54 | ||
| Q2 24 | $0.00 | $-0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | $208.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $261.7M |
| 总资产 | $645.8M | $349.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRNOUST
| Q1 26 | $307.8M | $208.6M | ||
| Q4 25 | $302.6M | $208.6M | ||
| Q3 25 | $286.6M | $244.5M | ||
| Q2 25 | $298.7M | $226.5M | ||
| Q1 25 | $281.8M | $168.2M | ||
| Q4 24 | $294.2M | $172.0M | ||
| Q3 24 | $305.7M | $151.4M | ||
| Q2 24 | $306.7M | $184.2M |
股东权益AMRNOUST
| Q1 26 | — | $261.7M | ||
| Q4 25 | $459.3M | $261.7M | ||
| Q3 25 | $458.9M | $247.4M | ||
| Q2 25 | $464.9M | $221.0M | ||
| Q1 25 | $473.7M | $167.9M | ||
| Q4 24 | $486.2M | $180.9M | ||
| Q3 24 | $531.4M | $171.7M | ||
| Q2 24 | $551.9M | $170.6M |
总资产AMRNOUST
| Q1 26 | $645.8M | $349.5M | ||
| Q4 25 | $670.8M | $349.5M | ||
| Q3 25 | $659.8M | $353.8M | ||
| Q2 25 | $670.1M | $321.8M | ||
| Q1 25 | $655.7M | $268.6M | ||
| Q4 24 | $685.3M | $276.1M | ||
| Q3 24 | $750.6M | $255.2M | ||
| Q2 24 | $799.9M | $309.9M |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
OUST
| Product revenue | $41.0M | 66% |
| Royalties | $21.2M | 34% |
